Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~o Patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of screening visit treated with basal insulin in combination with oral antihyperglycemic drugs (OADs) for at least 6 months before screening visit;~Exclusion criteria:~* Age \< 18 years at screening visit;~* BMI(body mass index) ≥ 35 kg/m2 at screening visit;~* HbA1c \< 7.0% or \> 10% (national glycohemoglobin standardization program \[NGSP\] value) at screening visit;~* Diabetes other than type 2 diabetes mellitus;~* Patients on self-monitoring of blood glucose less than 6 months before screening visit;~* Patients using pre-mix insulins, insulin detemir at 2 times or more a day, or GLP 1 receptor agonists in the last 3 months before screening visit;~* Patients using mealtime insulin (rapid-acting insulin analogue and short-acting insulin) for more than 10 days in the last 3 months before screening visit;~* Use of insulin pump in the last 6 months before screening visit;~* Initiation of new glucose-lowering medications and/or weight loss drugs in the last 3 months before screening visit;~* Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit;~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New formulation of insulin glargine (Type: EXPERIMENTAL): once daily in the evening on-top of oral antihyperglycemic drug (OADs)
- Lantus (insulin glargine) (Type: ACTIVE_COMPARATOR): once daily in the evening on-top of OADs

Based on this trial design, predict the completion outcome and termination type (if applicable).